At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 212 enrolled
Drug / intervention
BNC210 +1 moredrug
Likely dose
BNC210 900 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b, Randomized, Double Blind, Two Arm Study to Investigate the Effects of BNC210 Tablet Formulation Compared to Placebo in Adults With Post-Traumatic Stress Disorder (PTSD)
In Brief
A Phase 2 clinical trial evaluating BNC210 and Placebo for Post-Traumatic Stress Disorder. Completed, enrolled 212 participants across 32 sites in 2 countries.
Detailed Summary
The purpose of this study is to assess the effects of BNC210 compared to placebo on Post-Traumatic Stress Disorder (PTSD) symptom severity as measured by the Clinician Administered PTSD scale for The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (CAPS-5) Total Symptom Severity Scores.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPost-Traumatic Stress Disorder
CountriesUnited Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedJul 2021
Enrollment StartJul 2021
Primary CompletionJul 2023
Study CompletionAug 2023
TodayJul 2026
First PostedJul 6, 2021
Enrollment StartJul 27, 2021
Primary CompletionJul 25, 2023
Study CompletionAug 14, 2023
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 5.0 years ago
Interventions
BNC210drug
BNC210 900 mg twice daily (b.i.d.) for 12 weeks
Placebodrug
Placebo twice daily (b.i.d.) for 12 weeks